Hypera (HYPE3) Stock Overview
Operates as a pharmaceutical company in Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
HYPE3 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Hypera S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$23.72 |
| 52 Week High | R$28.87 |
| 52 Week Low | R$18.32 |
| Beta | 0.24 |
| 1 Month Change | 0.68% |
| 3 Month Change | -7.85% |
| 1 Year Change | 23.67% |
| 3 Year Change | -47.38% |
| 5 Year Change | -29.86% |
| Change since IPO | 184.07% |
Recent News & Updates
Recent updates
Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
Dec 28
What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E
Dec 01Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think
Nov 05Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Sep 05Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next
Aug 10The Price Is Right For Hypera S.A. (BVMF:HYPE3)
Jun 15Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Apr 23Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 27
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E
Feb 24More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%
Nov 21We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Nov 14Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
Oct 03We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Jul 13Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
Jun 20Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 16Is Hypera (BVMF:HYPE3) A Risky Investment?
Feb 21Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Jan 09Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
Dec 22Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Nov 02Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Aug 27Is Hypera (BVMF:HYPE3) A Risky Investment?
Jul 21We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Apr 15With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
Feb 19We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
Jan 03Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
Oct 11Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Jul 19Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
Jun 28Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Apr 14I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Mar 25Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Mar 04Shareholder Returns
| HYPE3 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | -7.5% | -4.4% | 1.4% |
| 1Y | 23.7% | 1.1% | 31.4% |
Return vs Industry: HYPE3 exceeded the BR Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: HYPE3 underperformed the BR Market which returned 31.4% over the past year.
Price Volatility
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 9.2% |
| 10% least volatile stocks in BR Market | 1.7% |
Stable Share Price: HYPE3 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: HYPE3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10,481 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
Hypera S.A. Fundamentals Summary
| HYPE3 fundamental statistics | |
|---|---|
| Market cap | R$15.01b |
| Earnings (TTM) | R$825.30m |
| Revenue (TTM) | R$6.97b |
Is HYPE3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYPE3 income statement (TTM) | |
|---|---|
| Revenue | R$6.97b |
| Cost of Revenue | R$3.02b |
| Gross Profit | R$3.95b |
| Other Expenses | R$3.13b |
| Earnings | R$825.30m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 12, 2026
| Earnings per share (EPS) | 1.30 |
| Gross Margin | 56.70% |
| Net Profit Margin | 11.84% |
| Debt/Equity Ratio | 74.7% |
How did HYPE3 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 17:51 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hypera S.A. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |